NeoMercazole 20mg Tablets

*
Pharmacy Only: Prescription
  • Company:

    ADVANZ Pharma
  • Status:

    No Recent Update
  • Legal Category:

    Product subject to medical prescription which may be renewed (B)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

EDM Updated on 13 March 2024

File name

Medicinal products containing carbimazole or thiamazole.pdf

Reasons for updating

  • Add New Doc

Updated on 10 March 2023

File name

1.3.2 PIL-Delpharm-Clean-IE-English -20mg_ireland.pdf

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 10 March 2023

File name

1.3.2 PIL-Delpharm-Clean-IE-English -20mg.pdf

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 30 December 2021

File name

NeoMercazole 20mg tablets_SPC_IE.pdf

Reasons for updating

  • Improved presentation of SPC

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 30 December 2021

File name

NeoMercazole tablets_PIL_IE.pdf

Reasons for updating

  • New PIL for new product

Updated on 30 July 2019

File name

1.3.1 SPC-20mg- clean (002).pdf

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 06 August 2015

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may be renewed (B)

Updated on 06 August 2015

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 4.8 of the SPC was updated with ADR reporting statement.

Updated on 06 August 2015

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Free text change information supplied by the pharmaceutical company

Section 4.8 of the SPC was updated with ADR reporting statement.

Updated on 02 July 2014

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section:-2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Section:-4.1 Therapeutic indications
Section:-4.2 Posology and method of administration
Section:-4.3 Contraindications
Section:-4.4 Special warnings and precautions for use
Section:-4.5 Interaction with other medicinal products and other forms of interaction
Section:-4.6. Pregnancy and lactation
Section:-4.7 Effects on ability to drive and use machines
Section:-4.8 Undesirable effects
Section:-4.9 Overdose
Section:-5.1 Pharmacodynamic properties
Section:-5.2 Pharmacokinetic properties
Section:-5.3 Preclinical safety data
Section:-6.6 Special precautions for disposal and other handling
Section:-10. Date of revision of the text

Updated on 02 July 2014

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text

Free text change information supplied by the pharmaceutical company

Section:-2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Section:-4.1 Therapeutic indications
Section:-4.2 Posology and method of administration
Section:-4.3 Contraindications
Section:-4.4 Special warnings and precautions for use
Section:-4.5 Interaction with other medicinal products and other forms of interaction
Section:-4.6. Pregnancy and lactation
Section:-4.7 Effects on ability to drive and use machines
Section:-4.8 Undesirable effects
Section:-4.9 Overdose
Section:-5.1 Pharmacodynamic properties
Section:-5.2 Pharmacokinetic properties
Section:-5.3 Preclinical safety data
Section:-6.6 Special precautions for disposal and other handling
Section:-10. Date of revision of the text

Updated on 08 June 2011

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category:Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 08 June 2011

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Free text change information supplied by the pharmaceutical company

None provided